Form D · Biotechnology
Affini-T Therapeutics, Inc.
Watertown, MA · CIK 0002036455
Offering snapshot reported Oct 15, 2024 · SEC filing
- Reported sold
- $17.6M Offering amount: $17.6M
- Investors reported
- 65 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 15, 2024 | Initial | $17,617,952 | No comparison | 65 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-526689
Source: Form D, filed Oct 15, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kathy Bergsteinsson | Executive |
| Jill De Simone | Director |
| Daniel Faga | Director |
| Arjun Goyal | Director |
| Lucio Iannone | Director |
| Joseph Knowles | Director, Executive |
| Michael Varney | Director |
| Kathy Yi | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Forge Road, Suite 900
Watertown, MA, 02472
Watertown, MA, 02472